The agreement builds on the original partnership established in 1990 and the extended collaboration announced in December 2023, when BD was granted worldwide exclusivity (excluding China) for Bactiguard-coated Foley catheters. Bactiguard’s long standing partnership with BD has progressed steadily, supported by strengthened collaboration and the provision of Bactiguard’s technology expertise across both existing and new markets.

Today, the partnership spans the full value chain, from technology development to global market execution, and is focused on expanding adoption of Bactiguard’s infection prevention technology. Through coordinated expertise and commercial execution, Bactiguard and BD are advancing access to Bactiguard-coated Foley catheters worldwide. The restated long-term agreement strengthens the foundation for future growth, helping more patients and providers benefit from solutions designed to reduce infection risk and improve patient safety. 

“We are very pleased with how our partnership with BD has evolved, particularly over the past two years where our common focus has been on ensuring a smooth transition of new markets including obtaining regulatory approvals. The aim has been to ensure patient access to Bactiguard-coated Foley catheters, and we are fully aligned with BD to grow the Foley business. Our collaboration with BD and the progress made is a good example of the power and potential of our license-focused strategy; a partnership that is global, growing, and built on shared success,” says Christine Lind, CEO of Bactiguard.

Bringing together BD’s global leadership in urology with Bactiguard’s infection prevention technology enables healthcare systems to enhance patient safety through Foley catheters designed to help reduce the risk of catheter-associated infections. The collaboration between BD and Bactiguard will continue to deliver enhanced solutions for patients requiring catheterization across the globe.